Brighton, UK-based respiratory diseases specialist Enterprise Therapeutics has appointed Dr John Ford as chief executive officer, with immediate effect.
In his new role, Dr Ford will oversee the development of the company’s novel muco-regulatory therapies for patients suffering with chronic obstructive pulmonary disease, cystic fibrosis and severe asthma.
He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002.
Dr Ford also brings experience from Ario Pharma, where he is currently chief executive officer and co-founder, and Metrion Biosciences, where he serves as co-owner and investor director.
Previously, Dr Ford has worked as general manager of Akarna Therapeutics’ UK operations, chief operating officer of Dezima Pharma and a team leader for cell-based drug discovery campaigns at BioFocus Discovery.
Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John’s experience in ion channels, drug development, and biotech fundraising position him uniquely to lead Enterprise Therapeutics moving forward.
“His expertise will complement the existing team and we are thrilled to have him on board.”